VANGUARD ASSET MANAGEMENT, Ltd
Position in RXRX — Recursion Pharmaceuticals, Inc.
CIK 1680208
London, EC4N 8AF, X0
Position in RXRX
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$1,293,599
New position
Shares Held
421,368
first reported quarter
Ownership
0.080%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026VANGUARD ASSET MANAGEMENT, Ltd holds $838,163,075 across 150 Biotechnology names. RXRX ranks #68 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
442,177 | $197,449,717 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
176,342 | $136,248,882 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
219,235 | $72,538,284 | |
| 4 | INSM |
INSMED Inc
|
360,075 | $58,879,464 | |
| 5 | RPRX |
Royalty Pharma plc
|
806,145 | $38,670,775 | |
| 6 | INCY |
Incyte Corp
|
289,697 | $27,266,281 | |
| 7 | MRNA |
Moderna, Inc.
|
318,776 | $16,193,820 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
137,507 | $10,325,400 |
All Filings in RXRX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,293,599 | 421,368 | Shares | Defined | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||